P070: Durvalumab和紫杉醇联合治疗转移性三阴性乳腺癌的安全性和有效性:一项为期2年随访的开放标签I/II期试验

{"title":"P070: Durvalumab和紫杉醇联合治疗转移性三阴性乳腺癌的安全性和有效性:一项为期2年随访的开放标签I/II期试验","authors":"H. Ghebeh, Adher Al-Sayed, Kauser Suleman, Riham Eiada, A. Tulbah, T. Al-Tweigeri","doi":"10.1158/2326-6074.tumimm21-p070","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract P070: The safety and efficacy of Durvalumab and Paclitaxel combination in metastatic triple-negative breast cancer: An open-label phase I/II trial with 2-years follow-up\",\"authors\":\"H. Ghebeh, Adher Al-Sayed, Kauser Suleman, Riham Eiada, A. Tulbah, T. Al-Tweigeri\",\"doi\":\"10.1158/2326-6074.tumimm21-p070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":120683,\"journal\":{\"name\":\"Other Topics\",\"volume\":\"37 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Other Topics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6074.tumimm21-p070\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Other Topics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2326-6074.tumimm21-p070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}